Search Results for: macular degeneration

Parkinson’s IPS cell trial in Japan switching to allogeneic

Jun-Takahashi

What’s better for stem cell trials such as for vision loss or Parkinson’s Disease: allogeneic or autologous cells? In a major shift earlier this year, the induced pluripotent stem (IPS) cell trial in Japan for treatment of macular degeneration (MD) switched gears from using the patients’ own cells (called “autologous”) to using banked cells from

Parkinson’s IPS cell trial in Japan switching to allogeneic Read More »

New UK trial & Ocata: stem cell hope on vision impairment

Peter-Coffey-Lyndon-Da-Cruz

We’ve been hearing a lot this week about an important new clinical study for vision loss (macular degeneration) in the UK. This team is using retinal pigmented epithelial cells (RPEs) made from embryonic stem cells (ESC). They are now testing safety. The new work in the UK is Moorfields Eye Hospital is a great addition

New UK trial & Ocata: stem cell hope on vision impairment Read More »

Masayo Takahashi (高橋 政代) Receives Ogawa-Yamanaka Stem Cell Prize

Masayo-Takahashi

The winner of the inaugural Ogawa-Yamanaka Prize is Masayo Takahashi, MD, PhD. According to the Gladstone Institute press release, “Dr. Takahashi was awarded the prize for her trailblazing work leading the first clinical trial to use induced pluripotent stem (iPS) cells in humans.” The prize, including a $150,000 cash award, will be given at a ceremony

Masayo Takahashi (高橋 政代) Receives Ogawa-Yamanaka Stem Cell Prize Read More »

ISSCR President Sean Morrison on challenges and future of stem cell field

Sean-Morrison1

I recently chatted with Sean Morrison, current President of ISSCR, on his goals for the Society, where the stem cell field stands today, top challenges, and the future. 2020 update: read my new interview with Sean on cell therapies for COVID-19. What are your goals for your tenure as President of ISSCR? SM: ISSCR is the

ISSCR President Sean Morrison on challenges and future of stem cell field Read More »

IPS Cell Immunogenicity, Clinical Insights, & Possible Solutions

1-s2.0-S1934590915003203-fx1

Can cells produced from autologous induced pluripotent stem cell (IPSC or IPS cell) cultures sometimes be immunogenic in patients? This key question has remained somewhat unsettled due to varied findings over the years (e.g. see here), but many of us had generally felt in the last couple years that IPS cell derivative immunogenicity in an

IPS Cell Immunogenicity, Clinical Insights, & Possible Solutions Read More »